Abstract
Ocular disorders can significantly lower a patient’s quality of life. Centers for Disease Control and Prevention’s Vision Health Initiative have estimated that the number of people affected by age-related ocular diseases may be doubled in the United States by 2030. Although availability of newer therapeutics has improved the prognosis of ocular diseases, poor ocular bioavailability still remains a major concern. Combinations of pharmacodynamic and pharmacokinetic barriers have been known to determine the amount of drug delivered to the target tissue. However, presence of membrane transporters and metabolizing enzymes pose a significant challenge to ocular drug disposition. Scientific literature confirms the expression of efflux/ATP-binding cassette transporters, influx/solute carrier transporters and several metabolic enzymes including oxidoreductases, hydrolases and transferases in different ocular tissues. Therefore, this review article describes the anatomical features of the eye and various barriers regulating ocular drug disposition. Differential expression of membrane transporters and metabolizing enzymes in normal and diseased states are briefly discussed. Further, the significance of transporter- metabolism interplay in ophthalmic drug design and various ocular drug delivery strategies are also outlined.
Keywords: Age-related eye diseases, drug delivery, membrane transporters, metabolizing enzymes, pharmacodynamic, pharmacokinetic and tissue localization.
Current Drug Metabolism
Title:Role of Membrane Transporters and Metabolizing Enzymes in Ocular Drug Delivery
Volume: 15 Issue: 7
Author(s): Ramya Krishna Vadlapatla, Aswani Dutt Vadlapudi, Dhananjay Pal and Ashim K. Mitra
Affiliation:
Keywords: Age-related eye diseases, drug delivery, membrane transporters, metabolizing enzymes, pharmacodynamic, pharmacokinetic and tissue localization.
Abstract: Ocular disorders can significantly lower a patient’s quality of life. Centers for Disease Control and Prevention’s Vision Health Initiative have estimated that the number of people affected by age-related ocular diseases may be doubled in the United States by 2030. Although availability of newer therapeutics has improved the prognosis of ocular diseases, poor ocular bioavailability still remains a major concern. Combinations of pharmacodynamic and pharmacokinetic barriers have been known to determine the amount of drug delivered to the target tissue. However, presence of membrane transporters and metabolizing enzymes pose a significant challenge to ocular drug disposition. Scientific literature confirms the expression of efflux/ATP-binding cassette transporters, influx/solute carrier transporters and several metabolic enzymes including oxidoreductases, hydrolases and transferases in different ocular tissues. Therefore, this review article describes the anatomical features of the eye and various barriers regulating ocular drug disposition. Differential expression of membrane transporters and metabolizing enzymes in normal and diseased states are briefly discussed. Further, the significance of transporter- metabolism interplay in ophthalmic drug design and various ocular drug delivery strategies are also outlined.
Export Options
About this article
Cite this article as:
Vadlapatla Krishna Ramya, Vadlapudi Dutt Aswani, Pal Dhananjay and Mitra K. Ashim, Role of Membrane Transporters and Metabolizing Enzymes in Ocular Drug Delivery, Current Drug Metabolism 2014; 15 (7) . https://dx.doi.org/10.2174/1389200215666140926152459
DOI https://dx.doi.org/10.2174/1389200215666140926152459 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
TiO2-Nanowired Delivery of Mesenchymal Stem Cells Thwarts Diabetes- Induced Exacerbation of Brain Pathology in Heat Stroke: An Experimental Study in the Rat Using Morphological and Biochemical Approaches
CNS & Neurological Disorders - Drug Targets Remdesivir and Hydroxychloroquine: A Compassionate Use in Covid-19
Current Drug Targets Attenuation of Hydroxyl Radical Formation by Extracted Constituent of Moringa oleifera Lam
Current Chemical Biology New Patents on Topical Anesthetics
Recent Patents on Inflammation & Allergy Drug Discovery Pathophysiology of Sepsis in the Elderly: Clinical Impact and Therapeutic Considerations
Current Drug Targets GPR55 and its Interaction with Membrane Lipids: Comparison with Other Endocannabinoid-Binding Receptors
Current Medicinal Chemistry Peptides for In Vivo Target-Specific Cancer Imaging
Mini-Reviews in Medicinal Chemistry Intradialytic Hypertension: An Under-recognized Cardiovascular Risk Factor. What is the Evidence?
Current Hypertension Reviews Cognitive Function and Heart Failure: The Role of the Adrenergic System
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Vascularization of Engineered Tissues: Approaches to Promote Angiogenesis in Biomaterials
Current Topics in Medicinal Chemistry Oligonucleotide-based Gene Therapy for Cardiovascular Disease Are Oligonucleotide Therapeutics Novel Cardiovascular Drugs
Current Drug Targets The Discovery and Development of Drug Combinations for the Treatment of Various Diseases from Patent Literature (1980-Present)
Current Topics in Medicinal Chemistry Resuscitation of the Patient with the Functionally Univentricular Heart
Current Pediatric Reviews Targeting Trail Towards the Clinic
Current Drug Targets Discovery and Advancement of Farnesyl Transferase Inhibitors as Potential Anticancer Therapeutic Agents: SCH 66336 a Case Study
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Genesis of Dihydropyrimidinone Calcium Channel Blockers: Recent Progress in Structure-Activity Relationships and Other Effects
Mini-Reviews in Medicinal Chemistry A Critical Review of Atypical Antipsychotic Utilization: Comparing Monotherapy with Polypharmacy and Augmentation
Current Medicinal Chemistry Fabry Disease Cardiomyopathy: from Genes to Clinical Manifestations
Current Pharmaceutical Biotechnology Pharmacology and Therapeutic Potential of Sigma1 Receptor Ligands
Current Neuropharmacology Other Proteins Involved in Parkinson's Disease and Related Disorders
Current Protein & Peptide Science